Praxis Precision Medicines, Inc. (PRAX)
| Market Cap | 984.89M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -70.32M |
| Shares Out | 38.63M |
| EPS (ttm) | -7.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $27.62 |
| Previous Close | $26.33 |
| Change ($) | 1.29 |
| Change (%) | 4.90% |
| Day's Open | 26.42 |
| Day's Range | 25.90 - 28.00 |
| Day's Volume | 130,934 |
| 52-Week Range | 23.90 - 60.95 |
PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022 PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ther...
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -
NEW YORK, Nov. 11, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. ("Praxis" or the "Company") (NASDAQ: PRAX). Such investors are ad...
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
CAMBRIDGE, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
CAMBRIDGE, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of thera...
Praxis Precision Medicines Inc. has increased the number of shares it plans to sell in its initial public offering by 35%, as the Massachusetts-based biopharmaceutical company developing treatments for ...
Praxis Precision Medicines has filed proposed terms for its U.S. IPO.
Praxis Precision Medicines Inc. set terms for its initial public offering, in which the Massachusetts-based biopharmaceutical company developing treatments for central nervous system disorders looks to ...
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential... [Read more...]
| Industry Biotechnology | IPO Date Oct 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol PRAX |
Analyst Forecasts
According to 4 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is 66.00, which is an increase of 138.96% from the latest price.